Short answer
MapLight Therapeutics, Inc. (MPLT) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$61M
- EPS (diluted)
- −$1.34
Source: XBRL data from the MapLight Therapeutics, Inc. (MPLT) Q1 2026 10-Q on SEC EDGAR. USD.
MapLight Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to 10-K risk factors identified in the provided excerpt
- Liquidity risk: accumulated deficit $421.2 million despite $395.2 million cash, cash equivalents, and investments
- Clinical-development risk: multiple Phase 2 trials for ML-007C-MA and ML-004 require substantial additional capital
- Regulatory risk: product candidates require preclinical testing, clinical trials, and regulatory approval before commercialization
- Market risk: $0.9 million unrealized losses on available-for-sale investments amid current economic and market conditions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MapLight Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.